Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK-Reference-Cited by-同舟云学术

Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK

Published:2022-04-13 Issue:6 Volume:39 Page:2292-2301
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Gillmore Julian D.,Reilly Mary M.,Coats Caroline J.,Cooper Rob,Cox Helen,Coyne Mark R. E.,Green Andrew J.,McGowan Ruth,Moody William E.,Hawkins Philip N.

Funder

Alnylam Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02139-9.pdf

Reference35 articles.

1. Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6. https://doi.org/10.1186/s13023-017-0726-x.

2. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. https://doi.org/10.1186/1750-1172-8-31.

3. Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. https://doi.org/10.1038/s41582-019-0210-4.